The Maintenance of Early Responses and Achievement of Delayed Responses to Deucravacitinib Treatment in Psoriais: A 104-Week Real-World Study in Japan.

The tyrosine kinase 2 inhibitor deucravacitinib is effective for psoriasis. However, it is unclear whether early responses to deucravacitinib in real-world practice are maintained for 2 years and whether patients without early responses can achieve d…

Preview only. Read the full abstract at the source